
Peptides Are Coming to Telehealth Checkouts. Here Is What to Look For.
Big telehealth brands plan to sell peptides. Learn which ones have a legal path, what the LegitScript seal checks, and the red flags.
13 stories tagged Peptides. Browse all of Policy & Compounding

Big telehealth brands plan to sell peptides. Learn which ones have a legal path, what the LegitScript seal checks, and the red flags.

Most peptides in a wellness stack have zero human trials. See what the research shows, and the 12-year gap five basic habits produced.

An Australian lab tested 18 vials sold as retatrutide. One matched its label. See what the dosing errors were and why a purity test proves little.

Melanotan II is sold as a tanning shortcut. See the FDA's own safety language, the published case reports, and where the 2026 peptide review stands.

An FDA panel backed 6 of 7 peptides for the compounding list. See the votes, what each was proposed to treat, and what has to happen next.

An FDA panel meets July 23-24 to weigh whether 7 peptides can be compounded. See which peptides, what the FDA recommends, and what it means.

Some peptides are FDA-approved medicines and some "research" peptides are risky. A plain-language guide to telling safe sources from unsafe ones.

How to vet a peptide provider in 2026: licensed pharmacy, named clinician, honest labeling, plus free tools and red flags to know before you buy.

Lab testing finds many grey-market peptides miss their purity claims, with heavy metals and bacterial contamination in samples. Here is what to know.

Wondering about adding peptides to your GLP-1? Here is what is safe, what is not yet legal, and what your doctor needs to know.
The FDA removed 12 peptides from a restricted category in April 2026. What that means for access, safety, and your GLP-1 care.

What are peptides and how do they differ from GLP-1 medications? A plain-language guide to BPC-157, CJC-1295, ipamorelin, and more.

A plain-language refresh on the difference between a GLP-1 medication and a peptide, updated for 2026 and the arrival of non-peptide GLP-1 pills.